Phreesia reports developments tied to its patient activation platform for healthcare providers, life sciences companies and other organizations. The company’s recurring news includes quarterly results, stakeholder letters, patient intake, outreach, education and appointment-scheduling solutions, and the scale of patient visits enabled through its digital workflows.
Company updates also cover healthcare payment capabilities, including the completed AccessOne acquisition, credit-facility refinancing, and corporate governance or workplace recognition items. Phreesia’s news flow is centered on software, payments and engagement tools used across healthcare delivery and patient interactions.
Phreesia (NYSE: PHR) appointed Jon Kessler to its Board, effective April 6, 2026, while directors Edward L. Cahill and Michael Weintraub will retire at the 2026 Annual Meeting. The Board will reduce to seven members and a new chair will be named after Weintraub's retirement.
Since the 2019 IPO, revenue grew from about $100 million to over $460 million for the twelve months ended October 31, 2025, and Phreesia enabled roughly 170 million patient visits in 2024.
Phreesia (NYSE: PHR) will report fiscal fourth quarter and fiscal year 2026 results after market close on Monday, March 30, 2026. The company will publish a press release and quarterly stakeholder letter on its investor site, then host a conference call and webcast at 5:00 PM ET the same day.
Live participation details, conference dial‑in numbers, conference code 7404611, and an on‑demand replay (available ~90 days) are provided on the Events & Presentations page of ir.phreesia.com.
Phreesia (NYSE: PHR) announced that CEO and co-founder Chaim Indig was named to The Software Report’s Top 50 CEOs of 2025, his third time receiving the honor.
Phreesia supports more than 4,400 healthcare organizations with its SaaS platform. The award recognizes demonstrated leadership, measurable contributions, and sustained organizational performance.
Phreesia (NYSE: PHR) was named one of The Software Report’s Top 50 Software Companies of 2025 on December 18, 2025. This is the fourth consecutive year Phreesia made the list and the first time it ranked in the Top 10. The award cites product excellence, organizational strength, culture, growth, and management caliber.
In 2025 Phreesia introduced Phreesia VoiceAI, a conversational automation tool for healthcare phone calls, which the company said supports its goal of making care easier for patients and providers.
Phreesia (NYSE: PHR) reported fiscal Q3 2026 results for the quarter ended October 31, 2025: total revenue $120.3M (+13% YoY), AHSCs 4,520 (+7% YoY), and revenue per AHSC $26,622 (+6% YoY). Net income was $4.3M versus a net loss of $14.4M year-ago; Adjusted EBITDA $29.1M versus $9.8M year-ago. Cash and cash equivalents were $106.4M as of October 31, 2025.
Post-quarter, Phreesia completed the AccessOne acquisition for approximately $160M on November 12, 2025, funded in part by a $110M 364-day bridge loan. Fiscal 2026 outlook was updated to $479M–$481M revenue and $99M–$101M Adjusted EBITDA. Fiscal 2027 outlook introduced: $545M–$559M revenue (14–16% growth) and $125M–$135M Adjusted EBITDA; AccessOne is expected to represent ~6.5% of fiscal 2027 revenue.
Phreesia (NYSE: PHR) announced that Megan Turco, Director of Client Experience for Phreesia Network Solutions, was named to MM+M’s 2025 40 Under 40. Since joining in 2018, Turco advanced through five roles and scaled the Client Experience team from four people to more than 50. She leads a sales organization servicing 80+ life sciences and agency clients and has overseen programs that reached millions of patients.
The team exceeded targets for four consecutive years with double‑digit annual revenue growth, and internal surveys show 95% client ratings of very good/excellent and 94% reporting great service.
Phreesia (NASDAQ: PHR) was named to the 2025 Deloitte Technology Fast 500, which ranks the 500 fastest-growing tech, media, telecom, life sciences, fintech and energy tech companies in North America based on fiscal year revenue growth from 2021 to 2024. Phreesia said this is its first Fast 500 appearance and credited the recognition to team performance and its mission to simplify care. The release notes eligibility criteria for the list, including base-year revenues of at least $50,000, current-year revenues of at least $5 million, and a minimum four-year operating history. Phreesia reported it enabled approximately 170 million patient visits in 2024 (about 1 in 7 U.S. visits).
Phreesia (NYSE: PHR) will release its fiscal third quarter 2026 results after market close on Monday, Dec. 8, 2025. The company will post a press release and a quarterly stakeholder letter on its investor website at ir.phreesia.com.
Phreesia will host a live conference call and webcast on Dec. 8, 2025 at 5:00 PM Eastern; dial-in numbers and conference code are provided on the investor events page. A replay will be available on the same web link for approximately 90 days.
About Phreesia: a patient-activation platform that enabled approximately 170 million patient visits in 2024, serving healthcare providers and life sciences customers. For investor or media inquiries, contact details are listed on the company site.
Phreesia (NYSE: PHR) was named to the 2025 Capterra Shortlists in the Appointment Reminder and Appointment Scheduling categories on October 8, 2025.
This marks Phreesia's third and fourth shortlist placements in 2025 after earlier inclusion for Patient Engagement and Medical Scheduling. Phreesia reported an overall 4.3/5 rating on Capterra, and highlighted user feedback on reduced no-shows and fewer scheduling calls. The company said its digital tools support provider scheduling, patient engagement and outreach.
Founded in 2005, Phreesia enabled approximately 170 million patient visits in 2024, and provides patient intake and digital engagement solutions for healthcare organizations.
Phreesia (NYSE:PHR), a leading patient intake and activation platform, has been recognized on TIME's inaugural World's Top HealthTech Companies of 2025 list. The company received a 'very high' performance indicator in the Health Information & Management category. Phreesia's platform facilitated 170 million patient visits in 2024, representing approximately 1 in 7 healthcare visits across the United States.
The TIME recognition, developed in partnership with Statista, evaluates companies based on financial performance, reputation analysis, and online engagement across six market segments. Phreesia's digital solutions focus on patient intake, outreach, education, and activation, aiming to enhance patient experience and improve healthcare outcomes.
["Recognition as a top healthtech company by TIME magazine", "Platform handles 1 in 7 healthcare visits in the U.S.", "Significant scale with 170 million annual patient visits"]